A de novo formulation of metformin using chitosan-based nanomicelles for potential diabetes therapy

Mojtaba Abbasian, Parvaneh Bighlari, Farideh Mahmoodzadeh, Metin Hayri Acar, Mehdi Jaymand*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


A de novo formulation of metformin (MET) was developed through the physical loading of drug into a chitosan-grafted-[poly(acryl amide)-block-poly(acrylic acid)] [CS-g-(PAAm-b-PAA)] terpolymer. For this purpose, CS was functionazed with phthalic anhydride followed by 4-cyano, 4-[(phenylcarbothioyl)sulfanyl]pentanoic acid to produc a macro-RAFT agent (CS-CTA). Afterward, acryl amide and acrylic acid monomers were graft and block copolymerized onto the synthesized CS-CTA through a reversible addition–fragmentation chain transfer (RAFT) polymerization technique to afford CS-g-PAAm copolymer and CS-g-(PAAm-b-PAA) terpolymer, respectively. The fabricated CS-g-(PAAm-b-PAA) terpolymer was loaded with MET as an anti-diabetic drug, and its drug release behavior was evaluated in the body simulated environment. As results, it was concluded that the fabricated CS-g-(PAAm-b-PAA) nanosystem has high potential as de novo drug delivery system (DDS) for diabetes therapy, mainly due to controlled drug release profile in comparison with conventional formulations of MET.

Original languageEnglish
Article number48037
JournalJournal of Applied Polymer Science
Issue number41
Publication statusPublished - 5 Nov 2019

Bibliographical note

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.


Authors earnestly acknowledge the partial financial support from Payame Noor University, Tehran, Iran.

FundersFunder number
Payame Noor University


    • block copolymer
    • chitosan
    • drug delivery
    • metformin
    • RAFT polymerization


    Dive into the research topics of 'A de novo formulation of metformin using chitosan-based nanomicelles for potential diabetes therapy'. Together they form a unique fingerprint.

    Cite this